Advanced searches left 3/3

Rheumatoid Arthritis - PLOS

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

Association of atherogenic indices with C-reactive protein and risk factors to assess cardiovascular risk in rheumatoid arthritis patient at Tikur Anbessa Specialized Hospital, Addis Ababa

The risk of cardiovascular disease in RA patients is up by 2 folds or more than the general population. Objectives: One of the objectives of this study was to determine CVD risk by comparing atherogenic indices with C-reactive protein. Methods: This research was based on a hospital based comparative cross-sectional research design. The data was cleaned, coded, and loaded into Epi Data version 4. 6 software, which was exported to SPSS version 20 for further analysis of atherogenic indices, C-reactive protein, and risk factors, according to Epi Data version 4. 6. For multinomial logistic regression analysis, only variables with a p-value less than 0. 2 were chosen for binary linear regression analysis analysis. Multiple logistic regressions was used to determine the association of atherogenic indices with C-reactive protein and risk factors. Both RA patients and the control group were measured for atherogenic indices, as well as the control group. The results of atherogenic indices were highly correlated with cardiovascular risk factor. The patient's TC/HDL-Cratio value was 2. 38 folds higher than those with an elevated low density lipoprotein level. In addition, AIP of RA patients had elevated low density lipoprotein and triglycerides respectively, which was 5. 51 and 23. 65 folds higher. Conclusions: The results of this research indicated that TC/HDL-C, LDL/HDL-C ratio measurements, and an atherogenic index of plasma had a statistically significant association with elevated levels of low density lipoprotein and triglycerides. Consequently, the results of this report showed that atherogenic indices could play a potential role in the prediction and management of CVD risk in RA patients.

Source link: https://doi.org/10.1371/journal.pone.0269431


Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice

Nintedanib, a multi-tyrosine kinase inhibitor that is widely used to treat progressive interstitial lung disease, reduces the reduction in forced vital capacity in a variety of fibrosing interstitial lung diseases. However, patients treated with nintedanib's prognosis are poor. We investigated the effects of nintedanib in the lungs of induced-rheumatoid arthritis model mice, which cause rheumatoid arthritis and subsequent pulmonary fibrosis, in the hopes of improving nintedanib therapy. After treatment with nintedanib, we found 27 upregulated and 130 downregulated genes in the lungs of these mice's mice using next-generation sequencing. Hence, the present findings reveal a series of genes whose expression change may explain the effects of nintedanib on pulmonary fibrosis. These results are expected to contribute to the development of new nintedanib-based treatment of progressive fibrosing interstitial lung diseases.

Source link: https://doi.org/10.1371/journal.pone.0270056

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions